Overview

A Phase I Study of Intraperitoneal Hyperthermic Docetaxel

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the maximum tolerated dose of docetaxel administered intraperitoneally with heat at the time of second-look surgery in patients with stage II/III ovarian carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
James Graham Brown Cancer Center
University of Louisville
Collaborators:
James Graham Brown Cancer Center
University of Louisville
Treatments:
Docetaxel